川崎病预后血小板多少 [药物洗脱支架植入后抗血小板治疗对预后的影响] .docx

《川崎病预后血小板多少 [药物洗脱支架植入后抗血小板治疗对预后的影响] .docx》由会员分享，可在线阅读，更多相关《川崎病预后血小板多少 [药物洗脱支架植入后抗血小板治疗对预后的影响] .docx（3页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、川崎病预后血小板多少 药物洗脱支架植入后抗血小板治疗对预后的影响 摘 要 目的 视察冠心病患者药物洗脱支架植入后应用抗血小板药物的状况及其与预后的关系。方法 调查150例冠心病患者药物洗脱支架植入后应用抗血小板药物的状况,并对主要心脏不良事 件进行随访分析。 结果 平均随访时间(30.315.1)个月,术后98.7%患者应用阿司匹林,应用时间平均(19. 37.2)月;术后99.3%患者应用氯吡格雷,应用时间平均(8.64.7)月;随访1年后 ,阿司匹林及氯吡咯雷应用率分别为88.7%及85.3%,随访2年后,阿司匹林及氯吡咯雷应 用率为52.7%及3.3%,随访期间25.3%患者完全停用抗血

2、小板治疗。完全停止抗血小板药 物的患者主要心脏不良事务明显增加(18.4% vs 4.5%,P 参考文献 1Zhang Q, Xu B, Yang YJ, et al. Long_term efficacy and safety of Chi nese made sirolimus eluting stents: results, including off label usage, from twocentres over three yearsJ. Chin Med J (Engl), 2008,121(17):1670-1674. 2Rodriguez AE. Emerging drug

3、s for coronary restenosis: the role of systemicoral agents the in stent eraJ. Expert Opin Emerg Drugs, 2009,14(4):561-576. 3Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outco me of thrombosis after successful implantation of drug_eluting stentsJ. JAMA , 2005,293(17):2126-2130

4、. 4Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-elutin g stent implantation: incidence, timing, and relation to discontinuation of clop idogrel therapy over a 4_year periodJ. Eur Heart J, 2009,30(22):2714-2721. 5Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hyp

5、oresponsiv eness and nonresponsiveness in patients with coronary artery stentingJ. VascHealth Risk Manag, 2009,5:965-972. 6Wenaweser P, Dorffler_Melly J, Imboden K, et al. Stent thrombosis is asso ciated with an impaired response to antiplatelet therapyJ. J Am Coll Cardiol , 2005,45(11):1748-1752. 7

6、Mardikar HM, Hiremath MS, Moliterno DJ, et al. Optimal platelet inhibitioninpatients undergoing PCI: data from the Multicenter Registry of High_Risk Percu taneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) studyJ .Am Heart J, 2007,154(2):344.e1-5. 8Ayyanathan S, Hersh D, Coplan NL, et al. The problem of stent thrombosis as sociated with drug_eluting stents and the optimal duration of dual antiplatelettherapyJ. Prev Cardiol, 2009,12(2):59-64.